ArticleJournal of the American Society of Nephrology : JASN2014
Patient-reported and actionable safety events in CKD.
Article in Journal of the American Society of Nephrology : JASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Remote Usability Testing and Satisfaction with a Mobile Health Medication Inquiry System in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Chronic pain and analgesic use in CKD: implications for patient safety.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Article
- Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice.Clinical kidney journal · 2022Article
- Improving hospital safety for patients with chronic kidney disease: a mixed methods study.BMC nephrology · 2021Article
- Impact of Adverse Drug Reactions in Patients with End Stage Renal Disease in Greece.International journal of environmental research and public health · 2020Article
- A Patient Safety Educational Tool for Patients With Chronic Kidney Disease: Development and Usability Study.JMIR formative research · 2020Article
- GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists.Journal of clinical medicine · 2020Review
- Key methodological considerations for usability testing of electronic patient-reported outcome (ePRO) systems.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Review
- "I just have to take it" - patient safety in acute care: perspectives and experiences of patients with chronic kidney disease.BMC health services research · 2019Article
- Telemedicine to Promote Patient Safety: Use of Phone-Based Interactive Voice-Response System to Reduce Adverse Safety Events in Pre-dialysis CKD.Advances in chronic kidney disease · 2017Review
- Patient-Reported Safety Events in Chronic Kidney Disease Recorded With an Interactive Voice-Inquiry Dial-Response System: Monthly Report Analysis.Journal of medical Internet research · 2016Article
- Self-reported Medication Adherence and Adverse Patient Safety Events in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2015Article
- Maintaining safety in the dialysis facility.Clinical journal of the American Society of Nephrology : CJASN · 2015Review
- Insulin for the treatment of hyperkalemia: a double-edged sword?Clinical kidney journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Patients with CKD are at high risk for adverse safety events because of the complexity of their care and impaired renal function. Using data from our observational study of predialysis patients with CKD enrolled in the Safe Kidney Care study, we estimated the baseline frequency of adverse safety events and determined to what extent these events co-occur. We examined patient-reported adverse safety incidents (class I) and actionable safety findings (class II), conditioned on participant use of drugs that might cause such an event, and we used association analysis as a data-mining technique to identify co-occurrences of these events. Of 267 participants, 185 (69.3%) had at least one class I or II event, 102 (38.2%) had more than one event, and 48 (18.0%) had at least one event from both classes. The adjusted conditional rates of class I and class II events ranged from 2.9 to 57.6 per 100 patients and from 2.2 to 8.3 per 100 patients, respectively. The most common conditional class I and II events were patient-reported hypoglycemia and hyperkalemia (serum potassium>5.5 mEq/L), respectively. Reporting of hypoglycemia (in patients with diabetes) and falling or severe dizziness (in patients without diabetes) were most frequently paired with other adverse safety events. We conclude that adverse safety events are common and varied in CKD, with frequent association between disparate events. Further work is needed to define the CKD "safety phenotype" and identify patients at highest risk for adverse safety events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.